Merit Medical (MMSI) Stock Eyes Bigger Growth Run After Profit Outlook Lift

Merit Medical Systems stock ticked up about 2% to roughly US$85 after Q2, a measured move for a company that recently reported its strongest organic growth in three years and lifted full-year profit guidance. The short-term reaction looks calm. The longer-term takeaway is more ambitious.

Revenue reached US$418.8m, with organic constant currency growth of 9%, and management raised its 2026 non-GAAP earnings per share outlook to US$4.25 to US$4.35. For investors, the real story now sits in the multi-year growth plan that will follow the current 2026 program.

Is Merit Medical Systems trading at a genuine discount, or is the P/E simply reflecting slower growth expectations? See how the market price lines up against our fair value workup in the valuation analysis for Merit Medical Systems

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$418.8m vs. US$382.5m (up about 9.5%)
• Net Income, Q2 2026 vs. Q2 2025: US$38.8m vs. US$32.6m (up about 19.1%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.65 vs. US$0.55 (up about 18.1%)
• Net Profit Margin, Trailing 12 Months vs. Prior Year: 9.2% vs. 8.3% (higher margin on a trailing basis)

Prefer clean charts over another dense block of earnings figures? See Merit Medical Systems' full financial picture, including a clear view of its valuation, in our company report for Merit Medical Systems.

Merit Medical bullish thesis clears key execution tests

Bulls argue that Merit Medical Systems can compound growth by shifting the mix toward higher margin therapeutic platforms in oncology and endoscopy while integrating tuck in deals. Q2 gives real proof points. Organic constant currency growth of 9% was the strongest in three years and beat guidance by about 210 bps, with both Foundational and Therapeutic categories contributing. Acquisitions such as Biolife and C2 exceeded revenue expectations and are reported as on track from an integration standpoint. View Point Medical is already integrated with the OneMark launch tied to SCOUT radar localization targeting roughly 1.3 million US procedures. Non GAAP operating margin reached 22.6% and EPS grew 18% year on year, and management still chose to assume a full 12 month tariff headwind in guidance. That supports the idea of a higher quality, more resilient earnings base.

Bear case on tariffs, OEM and scaling not closed

Bears worry that tariffs, OEM lumpiness and scale constraints will cap Merit Medical Systems closer to organic growth with limited margin progress. Q2 does not remove those concerns. Management explicitly highlighted tariff uncertainty and the variable timing of refunds, and still bakes about US$16m of tariff cost into the 2026 EPS outlook. OEM revenue rebounded 15% year on year but is flagged as structurally lumpy and expected to grow only mid to high single digits over a year, which can make operating leverage harder to sustain. Renal therapies felt an earlier recall with only a partial recovery so far. Guidance for the back half remains cautious despite a strong first half, with Q3 margins guided below Q2 levels. That restraint, combined with references to competitive pressure and the work still required on integrations, keeps key bear arguments alive even as execution improves.

Compare Merit Medical Systems' execution against what institutional analysts are signaling on future returns by checking the consensus price target analysis for Merit Medical Systems.

Own Your Next Investing Move

If Merit Medical Systems' recent Q2 performance and updated 2026 outlook caught your attention, register for free with Simply Wall St and add it to your Watchlist to keep an eye on price versus fair value and wait for a setup that fits your plan. After you decide to take a position, keep the bigger picture clear by tracking your holdings through the Portfolio Command Center so you only get the updates that actually matter. Round out your process by tapping into the crowd wisdom inside the Community where you can see how other investors are thinking about the same risks and opportunities. By spotting hidden catalysts and potential red flags early, you give yourself a better chance to act with confidence and stay ahead of the market.

Seeking Alternatives Beyond Merit Medical Systems

Fresh ideas can move from quiet accumulation to full breakout before most investors even notice. Screen under the radar stocks while it matters and get in early.

• Spot cash rich companies with room to move before momentum takes off by scanning our curated list of solid balance sheet and fundamentals stocks (45 results).
• Ride structural themes with real earnings power as you comb through 69 profitable AI stocks that aren't just burning cash that could gain traction while attention is still scattered.
• Position ahead of potential capital rotations by checking 19 high quality undiscovered gems that may shift quickly from overlooked to heavily followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com